文献速递骨软组织肉瘤与黑色素瘤

外周血CD8效应记忆1型T细胞与伊匹木单抗治疗的IV期黑色素瘤患者结局相关

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
PubMed 文献 · Eur J Cancer · 2017-02-04

该研究在137例晚期黑色素瘤患者中,于伊匹木单抗治疗前及治疗不同时间点分析外周血单个核细胞,用流式细胞术检测基线初始和记忆T细胞比例并与总生存期(OS)关联。基线CD8效应记忆1型(EM1)T细胞频率>13%与更长OS(p=0.029)和更高临床缓解率(p=0.01)相关,EM1频率和M分期对OS有独立影响(风险比=1.5,p=0.033;风险比=1.9,p=0.007)。基线晚期分化效应记忆CD8细胞频率>23.8%与OS负相关(p=0.034)但与临床缓解无关;治疗后CD8细胞自基线下降与高临床缓解率强而持续相关。作者认为基线CD8 EM1细胞和CD8细胞变化对伊匹木单抗临床缓解有重要预测作用,需进一步验证这些候选生物标志物。

要点

  • 基线CD8 EM1 T细胞频率>13%与伊匹木单抗治疗晚期黑色素瘤患者更长OS和更高临床缓解率相关。
  • 基线晚期分化效应记忆CD8细胞频率>23.8%与OS负相关,但与临床缓解无关。
  • 治疗后CD8细胞自基线下降与高临床缓解率强而持续相关。

核心结论

  • 基线CD8 EM1细胞和CD8细胞变化对伊匹木单抗临床缓解可能具有重要预测作用。
  • 需进一步验证这些候选生物标志物。

研究设计与样本

  • 分析137例晚期黑色素瘤患者伊匹木单抗治疗前及治疗不同时间点的外周血单个核细胞。
  • 用流式细胞术检测基线初始和记忆T细胞比例并与OS关联,重点关注PD-1表达。

主要发现

  • 基线CD8 EM1 T细胞频率>13%与更长OS相关(p=0.029),并与更高临床缓解率相关(p=0.01)。
  • EM1细胞频率和M分期对OS有独立影响(风险比=1.5,p=0.033;风险比=1.9,p=0.007)。
  • 基线晚期分化效应记忆CD8细胞频率>23.8%与OS负相关(p=0.034),但与临床缓解无关。
  • 治疗后CD8细胞自基线下降至第二剂给药时及后续时间点与高临床缓解率强而持续相关。

局限性

  • 需进一步验证这些候选生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during treatment with ipilimumab in 137 late-stage melanoma patients. The proportions of baseline naïve and memory T-cells were measured by flow cytometry and correlated with OS, with an emphasis on PD-1 expression. High frequencies (>13%) of CD8 effector-memory type 1 (EM1) T-cells at baseline correlated with longer OS (p = 0.029) and higher clinical response rates (p = 0.01). The frequency of these EM1 cells and the M category had independent impacts on OS (hazard ratio = 1.5, p = 0.033; and hazard ratio = 1.9, p = 0.007). In contrast, high baseline frequencies of late stage-differentiated effector memory CD8 cells (>23.8%) were negatively associated with OS (p = 0.034) but did not correlate with clinical response. Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate. Our observations thus suggest an important predictive role of baseline CD8 EM1 cells and changes in CD8 cells for clinical response of ipilimumab. Further validation of these biomarker candidates is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wistuba-Hamprecht K, Martens A, Heubach F, et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur J Cancer. 2017. PMID: 28167454. doi:10.1016/j.ejca.2016.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。